Literature DB >> 26647759

Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease.

Kai Zhao1, Suhong Ruan1, Lingling Yin1, Dongmei Zhao1, Chong Chen1, Bin Pan1, Lingyu Zeng1, Zhenyu Li2, Kailin Xu1.   

Abstract

Graft-versus-host disease (GVHD) as the predominant complication of allogeneic hematopoietic stem cell transplantation remains to be fully understood. It is known that the cytokines produced by allogeneic reactive effector CD4+ and CD8+ T cells are involved in GVHD. However, the regulation and coordination of IFN-γ-producing and IL-17-producing effector T cells remain unclear. The present study aimed to investigate the dynamic changes of alloantigen-specific effector CD4+ T and CD8+ T cell subsets by flow cytometry, which produce inflammatory cytokines involved in the multistep GVHD pathogenesis progress. The results demonstrated that IL-17-producing CD8+ T (Tc17) cells and IFN-γ+CD8+ T (Tc1) cells were detected in the early stage of GVHD. The differentiation of CD4+ T cells into Th1 cell (IFN-γ+CD4+ T) and Th17 (IL-17+CD4+ T) cells was later than that of the Tc1 and Tc17 cells. The effector CD4+ T and CD8+ T cell subsets either became exhausted or became memory cells, exhibiting a CD62L-CD44+ phenotype following marked expansion during GVHD. Furthermore, T cell-associated type I (IL-2 and IFN-γ) and type II (IL-4 and IL-10) classical cytokines exhibited coordinated dynamic regulation. It was concluded that the differentiation of cytokine-producing Tc1 and Tc17 cells may be the key step in the initiation of GVHD, whereas CD4+ effector Th1 and Th17 cells are considered to be pathophysiological factors leading to the continuous aggravation of GVHD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26647759     DOI: 10.3892/mmr.2015.4638

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.

Authors:  N J Geraghty; L Belfiore; D Ly; S R Adhikary; S J Fuller; W Varikatt; M L Sanderson-Smith; V Sluyter; S I Alexander; R Sluyter; D Watson
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

2.  Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.

Authors:  Sam R Adhikary; Peter Cuthbertson; Leigh Nicholson; Katrina M Bird; Chloe Sligar; Min Hu; Philip J O'Connell; Ronald Sluyter; Stephen I Alexander; Debbie Watson
Journal:  Immunology       Date:  2021-06-13       Impact factor: 7.215

3.  Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease.

Authors:  Adriana Gutiérrez-Hoya; Rubén López-Santiago; Jorge Vela-Ojeda; Laura Montiel-Cervantes; Octavio Rodríguez-Cortés; Víctor Rosales-García; Vladimir Paredes-Cervantes; Raúl Flores-Mejía; Daniela Sandoval-Borrego; Martha Moreno-Lafont
Journal:  J Immunol Res       Date:  2017-01-09       Impact factor: 4.818

4.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

Review 5.  The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.

Authors:  Sandeep Kumar; Nicholas D Leigh; Xuefang Cao
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

6.  IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model.

Authors:  Cuiping Zhang; Mina Delawary; Peng Huang; Jennifer A Korchak; Koji Suda; Abba C Zubair
Journal:  Cells       Date:  2021-11-10       Impact factor: 6.600

7.  β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.

Authors:  Hemn Mohammadpour; Joseph L Sarow; Cameron R MacDonald; George L Chen; Jingxin Qiu; Umesh C Sharma; Xuefang Cao; Megan M Herr; Theresa E Hahn; Bruce R Blazar; Elizabeth A Repasky; Philip L McCarthy
Journal:  JCI Insight       Date:  2020-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.